Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emavusertib in Relapsed or Refractory Primary Central Nervous System Lymphoma
NCT03328078Phase 2Recruiting
- Sponsor
- Curis, Inc.
- Start
- Dec 2017
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of emavusertib in primary central nervous system lymphoma (PCNSL), hematologic malignancy, sponsored by Curis, Inc.. Started Dec 2017; status: recruiting.
02
Drugs
emavusertib
03
Conditions
primary central nervous system lymphoma (PCNSL)hematologic malignancy
Beyond the preview
Go deeper on NCT03328078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03328078.